Survey of Cannabis Use in Patients With Chronic Inflammatory Arthritis

checkorphan
Learn more about:
Ankylosing spondylitis
Related Clinical Trial
The Effects of Baduanjin Qigong Exercise on Ankylosing Spondylitis: A Randomized Controlled Study Study to Assess Change in Disease Activity and Adverse Events of RINVOQ in Adult Participants With Ankylosing Spondylitis in the Real-World Japan Assessment of Predictive Factors for Persistence of Treatment After Substitution of Reference Adalimumab With the Fresenius Kabi Adalimumab Biosimilar in Patients With Chronic Inflammatory Diseases the Relationship Between Abnormal Modified Schober Index and Demographic Characteristics and Clinical Variables Modeling Spinal Mobility in Ankylosing Spondylitis: Towards New Telekinetic Biomarkers The Clinical Efficacy and the Changes of Immune Cells Subsets With Bioagents in Ankylosing Spondylitis Patients A Study to Evaluate the Efficacy and Safety of AK111 in Subjects With Active Ankylosing Spondylitis Hematological Parameters in Axial Spondyloarthritis Yuflyma® (Adalimumab), Patient Experience After Switching Ozone Therapy in Ankylosing Spondylitis Phase II Study of Hemay005 in Patients With Active Ankylosing Spondylitis Therapeutic Response to Tumor Necrosis Factor-alpha (TNF-alpha) Antagonists in Rheumatoid Arthritis. A Study Evaluating the Efficacy of Secukinumab 300mg in Chinese Adults With Active Ankylosing Spondylitis The Effects of Jing Si Herbal Tea Liquid Packets on Fatigue in Patients With Inflammatory Arthritis Evaluate the Preliminary Efficacy, Safety, and PK of Subcutaneous JS005 in Chinese Adult Patients With Active AS bIosimilar of aDalimumab, an European evAluation Survey of Cannabis Use in Patients With Chronic Inflammatory Arthritis

Brief Title

Survey of Cannabis Use in Patients With Chronic Inflammatory Arthritis

Official Title

Survey of Cannabis Use in Patients With Chronic Inflammatory Arthritis

Brief Summary

      Patients with inflammatory rheumatism very often have residual pain that is not easily
      relieved by conventional treatments. They can then use non-drug methods, such as
      physiotherapy, hypnosis or even cannabis.

      The aim of this study is to assess the percentage of patients who use cannabis to better
      relieve their pain or anxiety in chronic inflammatory rheumatism.

Detailed Description

      Thanks to a better understanding of the pathophysiological mechanisms of inflammatory
      rheumatism, rheumatology has known for several decades a growth in its therapeutic arsenal
      (csDMARDs, bDMARDs, tDMARDs). rheumatism control has thus been optimized.

      however, patients very often keep pain, anxiety, residual fatigue, poorly controlled by our
      conventional therapies. patients then turn to non-drug therapies, among which the use of
      cannabis.

      endocannabinoids have an analgesic and anti-inflammatory action recognized in pre-clinical
      trials. however, investigators currently lack the data to authorize its use in clinical
      rheumatology.

      the aim of this study is to determine the prevalence of cannabis users in patients with
      rheumatoid arthritis, ankylosing spondyloarthritis or psoriatic arthritis in our unit. as a
      second intention, investigators will refine the consumption characteristics. Investigators
      will also look for possible risk factors for consumption (sensitivity to pain, catastrophism,
      standard of living, anxiety, depression, rheumatic activity and quality of life).

Study Type

Observational

Primary Outcome

prevalence of cannabis use in patients with chronic inflammatory rheumatic conditions

Secondary Outcome

 Percentage of patients with problematic cannabis use

Condition

Rheumatoid Arthritis

Intervention

Cannabis questionnaire

Publications

* Includes publications given by the data provider as well as publications identified by National Clinical Trials Identifier (NCT ID) in Medline.

Recruitment Information

Recruitment Status

Behavioral

Estimated Enrollment

501

Start Date

May 19, 2020

Completion Date

March 19, 2021

Primary Completion Date

March 19, 2021

Eligibility Criteria

        Inclusion Criteria:

          -  Rheumatoid Arthritis (ACR 2010 Criteria)

          -  Ankylosing Spondylitis (New york or ASAS criteria)

          -  Psoriatic Arthritis (CASPAR criteria)

        Exclusion Criteria:

          -  Patient unable to complete questionnaires or unable to express informed consent

          -  Guardianship, trusteeship, deprivation of liberties, safeguard of justice

Gender

All

Ages

18 Years - N/A

Accepts Healthy Volunteers

No

Contacts

Sylvain Mathieu, ,

Location Countries

France

Location Countries

France

Administrative Informations

NCT ID

NCT04402554

Organization ID

RNI 2020 MATHIEU

Secondary IDs

2020-A00473-36

Responsible Party

Sponsor

Study Sponsor

University Hospital, Clermont-Ferrand

Study Sponsor

Sylvain Mathieu, Principal Investigator, University Hospital, Clermont-Ferrand

Verification Date

June 2021